CompletedPhase 2NCT00324415
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
Studying Carcinoma of the anal canal
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AIDS Malignancy Consortium
- Principal Investigator
- Joseph A. Sparano, MDAlbert Einstein College of Medicine
- Intervention
- cetuximab(biological)
- Enrollment
- 45 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2006 – 2016
Study locations (7)
- Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
- UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St Louis, Missouri, United States
- Albert Einstein Cancer Center at Albert Einstein College of Medicine, The Bronx, New York, United States
- Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
- Benaroya Research Institute at Virginia Mason Medical Center, Seattle, Washington, United States
Collaborators
National Cancer Institute (NCI) · The Emmes Company, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00324415 on ClinicalTrials.govOther trials for Carcinoma of the anal canal
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07029152Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure ProphylaxisUniversitair Ziekenhuis Brussel
- ACTIVE NOT RECRUITINGPHASE3NCT06866574A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese MalesXiamen University
- RECRUITINGPHASE2NCT06640283Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical OutcomesInstituto do Cancer do Estado de São Paulo
- RECRUITINGNANCT06792604Host Genome Methylation: a Screening Tool in Anal Cancer DetectionAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE3NCT06207981Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCAFederation Francophone de Cancerologie Digestive
- RECRUITINGPHASE2NCT05661188Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)Grupo Espanol Multidisciplinario del Cancer Digestivo
- RECRUITINGNCT06327568Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal SpecimensEuropean Institute of Oncology
- RECRUITINGNCT05438836Re-optimization Based Online Adaptive Radiotherapy of Anal CancerHerlev Hospital